29 May 2020: Weekly Roundup #11

Here’s what’s new on PathologyOutlines.com this week:

1. Updated Contact Us Page

We updated our Contact Us page with this paragraph:

Patients: This website is intended for pathologists and laboratory personnel, not for patients. We allow you to use it to obtain information, but ONLY if you agree that medical information is imperfect and must be interpreted using reasonable medical judgment. If you cannot be objective about medical information, please look elsewhere.

This was in response to a patient complaint about the excellent differentiated VIN page that was recently posted. The patient objected to this statement: “Differentiated vulvar intraepithelial neoplasia (dVIN) is the putative precursor lesion of HPV independent vulvar squamous cell carcinoma”. Although this statement is clear and correct, the patient had this condition and seemingly also had a fear of HPV. She wanted the word removed, even though the sentence clearly indicates that this condition is not HPV related.

In similar situations that may occur in the future, Dr. Pernick recommends that patients visit a website written for them specifically.

2. Digital Pathology Association (DPA) Survey

The Digital Pathology Association has been advocating for remote sign-out emergency use and needs your help to assess the safety and validity of remote sign-out of pathology cases. If you are doing remote sign-out or plan to do it, please participate in this short (5-10 minute) confidential survey. Your experience will help the DPA understand and evaluate the use of this technology beyond the current pandemic. 

We request that you complete this survey no later than Monday, June 1, 2020.

To receive further weekly roundups and other PathologyOutlines.com updates directly to your inbox, follow us below:

26 May 2020: Vendor Related Libraries

How can your business get information to Pathologists today? In the past, you could go to trade shows or visit them where they worked. Those options aren’t available today. 

In response, PathologyOutlines.com is setting up vendor related libraries on our website, tentatively scheduled to begin June 1. Your company can put information for Pathologists on these pages such as flyers, videos and your contact information. This helps everyone; Pathologists can find information on a website they use regularly and you can reach your broad audience of Pathologists.

We can design a page that highlights what your company wants to share with Pathologists in a place where they already come to increase their knowledge. Let us know if you want more information on advertising with the libraries by emailing Nat@PathologyOutlines.com or by filling out the contact form below.

25 May 2020: Textbook Updates

We have posted updated reviews of the following topics:

Esophagus > Esophagitis > Eosinophilic esophagitis
by Ryan C. Braunberger, M.D., Joshua A. Hanson, M.D.
Topic summary: Multifactorial, chronic eosinophilic inflammatory condition with no known cause. Diagnose if ≥ 15 eosinophils / HPF in proper clinical context. DD includes GERD. Great images and virtual slides.

Lymphoma & related disorders > T / NK cell disorders > Peripheral T cell lymphoma, not otherwise specified
by Matthew M. Klairmont, M.D., John Kim Choi, M.D., Ph.D.
Topic summary: Mature T cell lymphoma not otherwise classifiable within WHO. Aggressive clinical behavior. CD4 > CD8, EMA-, ALK-. DD includes Hodgkin lymphoma, ALK- ALCL. Extensive discussion.

Microbiology & parasitology > Microbiology – viruses > Diagnostic testing of SARS-CoV-2 (COVID-19)
by Samantha C. Wu, B.A., Patricia Tsang, M.D., M.B.A.
Topic summary: Timely topic with regular updates anticipated. Contains testing priorities and a list of commercially available SARS-CoV-2 assays in US with a comparison of their key features.

Vulva, vagina & female urethra > Vulva – carcinoma and precursor lesions > Differentiated type, vulvar intraepithelial neoplasia
by Matthias Choschzick, M.D.
Topic summary: Highly differentiated tumor with aggressive behavior (may become invasive). Has histological overlapping features to reactive or benign vulvar lesions but there is no reliable IHC or molecular markers to establish the diagnosis.

22 May 2020: Weekly Roundup #10

Here’s what’s new on PathologyOutlines.com this week:

1. Digital Pathology Association (DPA) Survey

The Digital Pathology Association has been advocating for remote sign-out emergency use and needs your help to assess the safety and validity of remote sign-out of pathology cases. If you are doing remote sign-out or plan to do it, please participate in this short (5-10 minute) confidential survey. Your experience will help the DPA understand and evaluate the use of this technology beyond the current pandemic. 

We request that you complete this survey no later than Monday, June 1, 2020.

2. Author Drafts

We have are swamped with many new author drafts. This will ultimately produce a better textbook, although our turnaround time is increasing a little. We continue to grapple with how best to standardize a textbook that has such disparate topics as solid tumors, hematopoietic tumors, informatics, management and transfusion medicine.

3. Google Search

There was a problem with Google links to our site redirecting to spam. This error was fixed Thursday afternoon. We apologize for the inconvenience and are implementing changes to reduce the likelihood of recurrence. Click here for more information.

To receive further weekly roundups and other PathologyOutlines.com updates directly to your inbox, follow us below:

21 May 2020: Textbook Updates

We have posted updated reviews of the following topics:

Breast malignant > In situ carcinoma > Ductal carcinoma in situ (DCIS)
by Gary Tozbikian, M.D.

CD Markers > CD38
by Frido Bruehl, M.D., Christian M. Schürch, M.D., Ph.D.
Topic summary: CD38 is an activation marker expressed on most hematopoietic cells, especially plasma cells and plasma cell neoplasms, and other malignancies. CD38 immunohistochemistry is rarely used in histopathology, but CD38 stainings are routinely used in flow cytometry to detect and quantify plasma cells. CD38 expression on CLL cells is associated with poor prognosis. Therapeutic anti-CD38 antibodies (e.g. daratumumab) are used for the treatment of multiple myeloma.

Cervix > General > Histology
by Kyle Devins, M.D., Lauren Schwartz, M.D.

Clinical chemistry > Other > Vitamin D
by Zhicheng Jin, Ph.D., Roger L. Bertholf, Ph.D., Xin Yi, Ph.D.

Companion diagnostic testing > Drugs of interest to pathologists > Olaparib
by Y. Albert Yeh, M.D., Ph.D.

We have added new images to the topics:

Breast nonmalignant > Benign tumors > Tubular adenoma
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

CD Markers > CD10
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Pleura > Mesothelial tumors > Diffuse malignant mesothelioma
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Pleura > Mesothelial tumors > Mesothelioma – epithelioid
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Skin inflammatory (nontumor) > Dermal granulomatous and necrobiotic reaction patterns > Sarcoidosis
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Stains & molecular markers > Calretinin
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Stains & molecular markers > Cytokeratin 5/6 and CK5
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Stains & molecular markers > Desmin
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Stains & molecular markers > Epithelial membrane antigen (EMA)
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

Stains & molecular markers > Estrogen receptor
microscopic images contributed by Jijgee Munkhdelger, M.D., Ph.D. and Andrey Bychkov, M.D., Ph.D.

20 May 2020: Industry News Updates

Check out our Industry News page. We have updated it with the following article / articles from:

Change HealthcareHow Business Intelligence Delivers Financial Insight to Outreach Labs
Hospital-based ‘outreach’ laboratories are under increasing financial pressure due to escalating costs, falling reimbursements, and growing competition. As a result, there’s little margin for error when it comes to financial management.Enter business intelligence (BI) tools, which can help analyze the past,interpret the present, and forecast the future, including identifying and addressing vulnerabilities before profitability is affected. Rest of article

20 May 2020: View prior Jobs, Fellowships, Conferences pages

We have now posted versions of the Jobs, Fellowships, and Conferences pages as of May 1, 2020. If you need to look up a prior ad, we maintain these files as of the first of each month (or close to it). See files below:

As of May 1, 2020: JobsFellowshipsConferences 

The format is the name of the file, plus yyyymm, where yyyy is the year and mm is the month.  So, for example, jobs posted as of May 1, 2020 are at http://www.pathologyoutlines.com/jobs202005.html.

Please contact us with any questions via email at CommentsPathOut@gmail.com.

19 May 2020: Biweekly Image Quiz #31

Author: Lisa Rooper, M.D.

A 30 year old man presented with a destructive sinonasal tumor. Biopsy findings are shown in the photomicrograph below. What molecular alteration is thought to be the driver of this tumor?

Select an answer:

A. Mutations in IDH2

B. EWSR1 translocations

C. NUT1 translocations

D. Inactivation of SMARCB1

To sign up for our biweekly image quiz newsletters and more, visit pathologyoutlines.com/subscribe.html.

To receive all PathologyOutlines.com updates directly to your email, follow our blog below:

15 May 2020: Copyright Policies

In lieu of a weekly roundup this week, we thought it would be best to tell you about our copyright policies.

We frequently get copyright related questions. All material on our website is protected by our copyright, which does not extend to material accessible by links to outside websites. Anyone may link to any page of PathologyOutlines.com at any time as long as (a) you credit the information to “courtesy of PathologyOutlines.com”, (b) you do not misrepresent the content as your own and (c) you do not charge for accessing this information. We do not require you to tell us about these links.

We do NOT allow you to copy paragraphs or pages of text to your website. This is a violation of U.S. copyright law and subjects you to civil and criminal penalties, regardless of your use of the material. We have had web pages removed or websites shut down that violated our copyright in these ways. If you want to reference our material, use a link instead. This not only spares you the legal process but also allows your visitors to see the most current information on our website. If unsure, please review fair use or contact Dr. Pernick at Nat@PathologyOutlines.com.

For more information, visit http://www.pathologyoutlines.com/copyrightinfo.html

To receive further PathologyOutlines.com updates directly to your email, follow us below:

14 May 2020: Textbook Updates

We have posted updated reviews of the following topics:

Bone marrow neoplastic > AML not otherwise categorized > Acute erythroid leukemia (AML-M6)
by Huifei Liu, M.D., Ph.D.
Topic summary: Update per revised 2017 WHO classification with incorporation of recent research findings.

Colon nontumor > Colitis (noninfectious) > Mycophenolate mofetil associated colitis
by Catherine E. Hagen, M.D.

Salivary glands > Primary salivary gland neoplasms – malignant > Polymorphous adenocarcinoma
by Bin Xu, M.D., Ph.D.
Topic summary: Updated topic with new: figures, cases reports, expanded microscopic, gross, and molecular description, review of immunohistochemistry and board review style questions.

Thyroid gland > Bethesda system > Hürthle cell neoplasm
by Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.

Transfusion medicine > Immunotherapy > CAR T cell therapy
by Melissa R. George, D.O.
Topic summary: Chimeric antigen receptor T cells (CAR T) are a form of gene transfer therapy involving the engineering of T cells to produce surface receptors targeted to specific cell surface receptors, primarily used to treat hematologic malignancies, although their application is being explored for other malignancies and conditions.